We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Molecular Test for H. pylori Evaluated

By LabMedica International staff writers
Posted on 15 Jan 2018
Helicobacter pylori is a Gram-negative bacterium that can cause chronic stomach infections and is therefore known as the main cause of gastric ulcers and subsequently for the development of gastric cancer if untreated.

In times of increasing antibiotic resistance, the need for more rapid resistance screening procedures that replace conventional cultural methods gain importance as H. More...
pylori is a fastidious and slow growing bacterium that can make susceptibility testing from culture a time consuming and challenging task.

Medical microbiologists at the University of Zurich (Switzerland) used a set of 60 H. pylori strains from the culture collection of their Institute of Medical Microbiology. These strains were isolated between 2013 and 2015 from gastric biopsies that were sent to the laboratory for susceptibility testing after clarithromycin (CLR) treatment failure. The strains were intentionally selected based on their phenotypic resistance status to get an evenly distributed number of CLR susceptible (minimum inhibitory concentrations (MIC) ≤0.25 mg/L) and CLR resistant strains (MIC from 0.016 to 256 mg/L).

The scientists compared the CLR susceptibility testing by E-Test and the Lightmix Real-Time Polymerase Chain Reaction assay. A Veriti Thermal Cycler was used for the cycle sequencing program. The team found high concordance (95%) between phenotypical CLR resistance screening by E-Test and the Lightmix RT-PCR. Discrepant results were verified by sequencing of the 23S rRNA gene that always confirmed the results obtained by Lightmix RT-PCR. Furthermore, H. pylori was detected in clinical biopsy and stool specimens by Lightmix RT-PCR that identified the correct H. pylori genotype.

The authors concluded that their data showed that there is a strong association between specific mutations in the 23S rDNA and CLR resistance. The RT-PCR proved to be an exceptional tool for a fast and reliable detection of H. pylori. Furthermore, it allows for CLR resistance screening within a few hours prior to the prescription of an antibiotic therapy and should drastically reduce the cases of treatment failure. The study was published in the January 2018 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
University of Zurich


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.